Olumiant

Active substance

Olumiant

Holder

S.A. Eli Lilly N.V.

Status

closed

Indication

moderate to severe atopic dermatitis (AD), defined as EASI score ≥16 before start of treatment, in adult patients that qualify for systemic treatment

Public documents 

Approbation

Information for the patient

Informed consent

Last update

01/06/2022